Illumina Inc. (ILMN)
NASDAQ: ILMNHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ILMN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.15B
- P/E (TTM)
- 33.19
- Forward P/E
- 31.19
- EPS (TTM)
- $5.81
- Dividend yield
- None
- 52-week range
- 112.65 – 309.35
- Day range
- 191.28 – 199.24
- Volume / Avg
- 1.95M / 2.82M
- Beta
- —
- Shares outstanding
- 151.20M
52-week range
ILMN stock today
On Nov 20, ILMN ended the session at $192.82, shedding $7.83 (3.90%), versus the S&P 500's 3.70% decline. At this level, ILMN sits in the middle of its 52-week range of $112.65 to $309.35: 37.7% below the high, set on Oct 6, 2026 and 71.2% above the low. ILMN is up 47.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 55.7%.
At 33.2x trailing earnings, Illumina trades above the peer-group median of 25.7x. Its forward P/E of 31.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Illumina
Company profileIllumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Jacob Thaysen Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 8,600
- IPO year
- 2000
- Website
- illumina.com
Financial highlights
Full financialsIn fiscal 2025, Illumina generated $4.34 billion in revenue, down 0.7% from fiscal 2024, its first annual decline since 2024. Net income was $850.0 million, for a net margin of 19.6% versus a median of -25.8% in the prior 5 years. Gross margin was 66.1% (up from 65.4%) and operating margin 18.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.34B | $4.37B | $4.50B | $4.58B | $4.53B |
| Growth | -0.66% | -2.93% | -1.75% | +1.28% | +39.73% |
| Net income | $850.00M | $-1.22B | $-1.16B | $-4.40B | $762.00M |
| EPS (diluted) | $5.45 | $-7.69 | $-7.34 | $-28.00 | $5.04 |
Analyst forecast
ForecastConsensus (21 analysts)
buy
Avg. price target
$261.45+35.59%
- Strong buy 4
- Buy 6
- Hold 7
- Sell 1
- Strong sell 3
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $1.34 vs $1.36
- Surprise
- -1.47%
ILMN news
All ILMN news- RPRX vs. ILMN: Which Stock Should Value Investors Buy Now?NasdaqRPRX, ILMN
- Illumina Wins Virtual Cell Challenge, Powered by Billion Cell AtlasPR Newswire
- Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive?NasdaqILMN, IDXX, PODD, BLCO
- Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Illumina Sees Strong Clinical Demand, but Research Recovery Remains in QuestionNasdaq
- Illumina Bets on Clinical Demand for Growth as Research Funding Uncertainty PersistsNasdaq
- Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference TranscriptSeeking Alpha
- iShares Biotechnology ETF Experiences Big OutflowNasdaqIBB, ARGX, RVMD, ILMN
Illumina peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LHLabcorp Holdings Inc. | 367.13 | -0.47% | $29.81B | vs ILMN |
| DGXQuest Diagnostics Incorporated | 258.28 | -0.31% | $28.42B | vs ILMN |
| CNCCentene Corporation | 63.78 | -2.74% | $31.58B | vs ILMN |
| GHGuardant Health Inc. | 145.83 | +0.16% | $19.73B | vs ILMN |
| NTRANatera Inc. | 273.40 | -5.70% | $39.64B | vs ILMN |
| HUMHumana Inc. | 390.00 | +2.63% | $46.84B | vs ILMN |
| MOHMolina Healthcare Inc | 198.39 | -2.43% | $10.36B | vs ILMN |
| HSICHenry Schein Inc. | 83.52 | -1.51% | $9.23B | vs ILMN |
Indexes, lists and sector
Index membership
Illumina stock FAQ
What is Illumina's stock price today?
ILMN last traded at $192.82 as of Nov 20, 4:00 PM EST, down 3.90% on the day. Prices are delayed at least 15 minutes.
Does Illumina pay a dividend?
No. Illumina does not currently pay a regular cash dividend.
What is ILMN's P/E ratio?
ILMN trades at a trailing P/E ratio of 33.19 and a forward P/E of 31.19, compared with a median of 25.7 for its closest peers.
Is Illumina in the S&P 500?
Yes. Illumina (ILMN) is a constituent of the S&P 500 index.
Who is Illumina's CEO?
Mr. Jacob Thaysen Ph.D. is the chief executive officer of Illumina Inc., which has about 8,600 employees.
Has ILMN ever split its stock?
Yes. The most recent ILMN stock split was a 1028-for-1000 split on Jun 25, 2024, one of 2 splits on record.
What is the ILMN 52-week high?
The 52-week high for ILMN is $309.35 and the 52-week low is $112.65. The stock is currently 37.7% below its high.